Understanding MYD1 Recombinant Protein: A Key Tool for Innate Immunity and Inflammation Research

Concept

MYD1 recombinant protein—referring to the bioengineered form of myeloid differentiation factor 1 (MYD1, typically MYD88, Myeloid Differentiation Primary Response 88)—is a critical molecular tool produced via advanced molecular biology techniques. As a core adaptor protein in the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) signaling pathway, MYD1 mediates innate immune responses by bridging upstream receptors and downstream signaling cascades. The recombinant version retains the native protein’s biological functions, featuring two conserved structural domains: an N-terminal Death Domain (DD) that facilitates interactions with upstream receptors (e.g., TLR4, IL-1R) and downstream kinases (e.g., IRAK1/4), and a C-terminal Toll/IL-1 Receptor Homologous Domain (TIR Domain) responsible for signal transduction specificity. With a full-length molecular weight of approximately 75 kDa (comprising ~690 amino acids), MYD1 recombinant protein is engineered with optional fusion tags (e.g., His-tag, GST-tag) to enhance solubility and purification efficiency—with rigorous activity validation ensuring tags do not interfere with its adaptor function. It serves as an indispensable tool for dissecting innate immune mechanisms, exploring inflammation-related disease pathogenesis, and accelerating targeted drug development.

Research Frontier

MYD1 (MYD88) and its recombinant form are at the forefront of innate immunity and inflammation research, with current advances focusing on three core directions: optimized expression/purification strategies for enhanced solubility and activity, structural and functional dissection of MYD1-mediated signaling complexes, and translational applications in drug discovery and vaccine development. Cutting-edge studies are refining prokaryotic, eukaryotic, and cell-free expression systems to address longstanding challenges such as low solubility of full-length MYD1 in prokaryotes. Structural biology techniques, including cryo-electron microscopy (cryo-EM), are unraveling the atomic details of MYD1-containing signaling complexes (e.g., MYD1-TLR4-IRAK4 ternary complexes), providing insights into signal transduction mechanisms. Additionally, MYD1 recombinant protein is increasingly being integrated into high-throughput screening platforms for identifying novel immunomodulators and vaccine adjuvants, driving advancements in the treatment of autoimmune diseases, infectious diseases, and inflammatory disorders.

Research Significance

MYD1 recombinant protein holds profound scientific and translational significance, serving as a cornerstone for advancing knowledge in innate immunity and enabling the development of novel therapeutic strategies for inflammation-related diseases.

In basic immunology research, it enables the precise reconstitution of TLR/IL-1R signaling pathways in vitro, facilitating the identification of key interaction partners, phosphorylation events, and regulatory mechanisms of MYD1. This knowledge is critical for understanding how the innate immune system recognizes pathogens and initiates inflammatory responses, as well as how dysregulation of these processes contributes to disease. Structural studies using MYD1 recombinant protein also provide the molecular basis for rational drug design, targeting MYD1-mediated protein-protein interactions.

In disease mechanism research, aberrant MYD1 signaling is linked to a wide range of inflammatory and autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and sepsis. MYD1 recombinant protein enables the development of diagnostic assays to detect disease-specific autoantibodies (e.g., anti-MYD1 antibodies in SLE patients) and elucidates how MYD1 dysregulation drives pathological inflammation—identifying potential therapeutic targets.

In translational research, MYD1 recombinant protein accelerates drug discovery by serving as a key component of high-throughput screening platforms for identifying small-molecule inhibitors of MYD1-mediated signaling. It also enhances vaccine development by acting as an adjuvant to boost antigen-specific immune responses, and supports the development of novel immunomodulators (e.g., MYD1-derived peptides) for treating immune-related disorders.

Related Mechanism and Product Application

Core Mechanism of MYD1 in TLR/IL-1R Signaling

MYD1 functions as a central adaptor in the TLR/IL-1R signaling pathway, mediating the transmission of pathogen-associated molecular pattern (PAMP) or damage-associated molecular pattern (DAMP) signals to downstream inflammatory cascades. The mechanism involves three key steps:

1. Receptor activation: Binding of PAMPs/DAMPs to TLRs (e.g., TLR4) or IL-1R induces receptor dimerization and recruitment of MYD1 via TIR domain-TIR domain interactions.
2. Signal complex assembly: MYD1’s DD domain mediates homotypic interactions with downstream IRAK family kinases (IRAK1/4), forming a signaling complex (MYDosome) that activates downstream kinase cascades.
3. Inflammatory response initiation: The activated kinase cascade phosphorylates and activates transcription factors such as NF-κB and AP-1, driving the expression of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and chemokines—initiating the innate immune response.

MYD1 recombinant protein recapitulates this native signaling function in vitro, enabling the systematic study of each step of the pathway, from receptor binding to transcription factor activation.

Advanced Expression and Purification Strategies

MYD1 recombinant protein is produced via three primary expression systems, each optimized for specific research applications, with standardized purification workflows ensuring high purity, activity, and stability:

1. Prokaryotic expression (E. coli BL21(DE3)): The most widely used system, optimized via codon adjustment and low-temperature induction (16–20°C) to achieve soluble MYD1 expression at 15–20 mg/L. Constructs often include an N-terminal His6 tag and solubilizing tag (e.g., MBP) to improve stability. Two-step purification (nickel column affinity chromatography + molecular sieve chromatography) yields protein with >95% purity and a final yield of 5–8 mg/L.
2. Eukaryotic expression (HEK293F cells): Enables eukaryotic-specific post-translational modifications, particularly phosphorylation of the TIR domain’s key tyrosine residue (Y158)—critical for full biological activity. Purification via Protein A affinity chromatography and ion exchange chromatography produces protein with 3–5 times higher activity than prokaryotically expressed MYD1, making it ideal for functional assays requiring native modifications.
3. Cell-free expression (wheat germ extract): A rapid production system that synthesizes 2–3 mg/mL MYD1 protein within 8 hours, eliminating the need for tag removal. It is particularly suitable for isotope labeling in nuclear magnetic resonance (NMR) structural studies.

Stability optimization: All purification processes include 5–10% glycerol and 1–2 mM DTT as stabilizers. Storage at -80°C maintains long-term stability, with <10% activity loss within 12 months. Additionally, oxidation-stable MYD1 variants (e.g., MYD1-OX with C113S/C196S double mutations) retain >90% activity after 4 weeks of storage at 4°C, simplifying experimental workflows.

Rigorous Functional Verification and Quality Control

To ensure reliability in research applications, MYD1 recombinant protein undergoes multi-level functional verification and strict quality control, with key criteria including:

• Protein-protein interaction validation: In vitro pull-down and surface plasmon resonance (SPR) confirm stable binding to the TLR4-TIR domain (binding constant Kd ≈ 50 nM).
• Signaling activity assay: 100 ng/mL recombinant MYD1 restores NF-κB reporter gene activity in MYD1-knockout THP-1 cells, increasing luciferase expression by 8–10 fold.
• Post-translational modification confirmation: Mass spectrometry verifies phosphorylation at key residues (Y158, S76) in eukaryotically expressed MYD1 (modification rate >90%).
• Physicochemical and purity checks: SEC-MALS confirms molecular weight (33.2 ± 1.5 kDa); circular dichroism (CD) spectroscopy detects typical α-helix content (~45%, with characteristic negative peaks at 208 nm and 222 nm); endotoxin levels <0.1 EU/μg (suitable for cell-based assays); batch-to-batch activity variation <15% (assessed via IRAK4 phosphorylation detection).

Diverse Applications in Immunological Research

MYD1 recombinant protein is a versatile tool with broad applications across innate immunity, inflammation, and translational research:

1. Signaling pathway dissection: In vitro reconstitution experiments using MYD1 recombinant protein identified the MYD1-TLR4-IRAK4 ternary complex as the minimal functional unit of TLR signaling (cryo-EM resolution 3.8 Å), clarifying the molecular basis of signal transduction.
2. High-throughput drug screening: Integrated into AlphaScreen-based platforms, it enables the rapid identification of small-molecule inhibitors (e.g., TJ-M2010-5) that specifically block the MYD1-TLR4 interaction (IC50 ≈ 5 μM), providing lead compounds for anti-inflammatory drug development.
3. Vaccine adjuvant development: Co-encapsulation of MYD1 recombinant protein with antigens in PLGA nanoparticles increases antigen-specific antibody titers by 10–20 fold, attributed to its ability to enhance dendritic cell (DC) maturation (CD86+CD80+ cell ratio increased by 60–80%).
4. Diagnostic assay development: Used as a standard in ELISA, it enables quantitative detection of anti-MYD1 autoantibodies in patient sera—with 30% positivity in SLE patients, offering a novel marker for disease subtyping.
5. Live cell imaging: Fluorescently labeled MYD1 (e.g., Alexa Fluor 647-MYD1) enables single-molecule tracking of its dynamic aggregation into 200–500 nm signal bodies after TLR activation, revealing spatiotemporal regulation of signaling.

Current Challenges and Future Development Directions

Despite its broad utility, MYD1 recombinant protein research faces key challenges that drive ongoing innovation:

• Preparation challenges: Full-length MYD1 expressed in prokaryotic systems exhibits low solubility (<30%), requiring novel molecular chaperone co-expression strategies.
• Functional gaps: The selective regulatory mechanisms of MYD1 across different TLR subtypes (e.g., TLR2 vs. TLR7) remain unclear, demanding further structural biology studies.
• Translational barriers: Recombinant MYD1 has a short in vivo half-life (~2 hours) and potential immunogenicity (especially tagged variants), while large-scale production cost-effectiveness needs improvement.

Future development directions over the next five years include:

1. Site-specific labeling: Integrating non-natural amino acid insertion technologies (e.g., pAzF) for precise cross-linking and imaging studies.
2. Reporter cell line development: Constructing MYD1-KO THP1-NF-κB-GFP gene-edited cell lines for high-throughput drug screening.
3. Peptide-based immunomodulators: Designing MYD1-derived peptides (e.g., TIR domain mimics) as novel, low-immunogenicity therapeutics.
4. Controllable in vivo expression: Exploring mRNA delivery technology to achieve targeted, regulated MYD1 expression in vivo.

MYD1 Recombinant Protein in ANT BIO PTE. LTD.’s Research Ecosystem

As a leading provider of life science reagents, ANT BIO PTE. LTD. leverages its UA sub-brand—specialized in recombinant protein development—to offer high-quality MYD1 recombinant protein tailored for immunological research. Our product adheres to the strictest expression, purification, and quality control standards, ensuring exceptional purity (>95%), activity, and batch consistency. It is available in multiple formats (prokaryotic/eukaryotic expression, tagged/untagged variants) to meet diverse experimental needs, from basic signaling pathway dissection to high-throughput drug screening and vaccine development.

Complementary to our MYD1 recombinant protein, ANT BIO PTE. LTD.’s Starter sub-brand provides recombinant rabbit monoclonal antibodies targeting key TLR/IL-1R signaling molecules (e.g., IRAK4, NF-κB), while our Absin sub-brand offers kits for NF-κB reporter gene assays and cytokine detection. This integrated toolchain supports end-to-end research workflows, from in vitro signal reconstitution to in vivo efficacy evaluation. Our professional technical team provides comprehensive support, including optimized experimental protocols, activity validation data, and troubleshooting guidance—empowering researchers to accelerate breakthroughs in innate immunity and inflammation research.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.